According to PTI reports, Fresenius Kabi Oncology has approached the Securities Appellate Tribunal (SAT) against market watchdog SEBI’s order on minimum 25% public shareholding and sought permission to de-list its shares from the stock exchanges.
The healthcare firm is among the 105 companies facing action of SEBI for not having complied to the minimum public holding requirements within the deadline of June 3, 2013.
The regulator has refused permission to the company for its delisting plans, as it had benefited from a specially designed offer-for-sale (OFS) route for expanding the public float of shares.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
